DXCM — DexCom Inc

DexCom Inc (DXCM) is a medical devices company listed on NASDAQ. It is led by Kevin Ronald Sayer, based in 6340 Sequence Drive, San Diego, CA, United States, 92121, with about 10,200 employees. DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Stelo, a new over-the-counter glucose biosensor designed for adults with prediabetes and Type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Latest reported DXCM revenue for 2025-09-30 was $1.21B. Net income was $283.8M. Revenue was up 4.5% from 2025-06-30 to 2025-09-30. DXCM currently screens at market cap $32.84B and trailing P/E 62.5.

Use this DXCM page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the DXCM quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the DXCM SEC filings page. Lician reads the product cache first so this HTML stays unique to DexCom Inc even when a live quote feed is slow.